118 related articles for article (PubMed ID: 37913894)
21. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
Singh P; Wig JD; Srinivasan R; Radotra BD
Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
[TBL] [Abstract][Full Text] [Related]
22. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
23. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.
Bardeesy N; Cheng KH; Berger JH; Chu GC; Pahler J; Olson P; Hezel AF; Horner J; Lauwers GY; Hanahan D; DePinho RA
Genes Dev; 2006 Nov; 20(22):3130-46. PubMed ID: 17114584
[TBL] [Abstract][Full Text] [Related]
24. Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer.
Patil S; Forster T; Reutlinger K; Kopp W; Versemann L; Spitalieri J; Gaedcke J; Ströbel P; Singh SK; Ellenrieder V; Neesse A; Hessmann E
Cells; 2021 Dec; 10(12):. PubMed ID: 34943970
[TBL] [Abstract][Full Text] [Related]
25. The transcription factor GLI1 interacts with SMAD proteins to modulate transforming growth factor β-induced gene expression in a p300/CREB-binding protein-associated factor (PCAF)-dependent manner.
Nye MD; Almada LL; Fernandez-Barrena MG; Marks DL; Elsawa SF; Vrabel A; Tolosa EJ; Ellenrieder V; Fernandez-Zapico ME
J Biol Chem; 2014 May; 289(22):15495-506. PubMed ID: 24739390
[TBL] [Abstract][Full Text] [Related]
26. Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer.
Hurwitz E; Parajuli P; Ozkan S; Prunier C; Nguyen TL; Campbell D; Friend C; Bryan AA; Lu TX; Smith SC; Razzaque MS; Xu K; Atfi A
J Cell Biol; 2023 Apr; 222(4):. PubMed ID: 36828547
[TBL] [Abstract][Full Text] [Related]
27. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation.
Wang C; Zhang T; Liao Q; Dai M; Guo J; Yang X; Tan W; Lin D; Wu C; Zhao Y
Protein Cell; 2021 Feb; 12(2):128-144. PubMed ID: 32737864
[TBL] [Abstract][Full Text] [Related]
28. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.
Diehl JN; Hibshman PS; Ozkan-Dagliyan I; Goodwin CM; Howard SV; Cox AD; Der CJ
Adv Cancer Res; 2022; 153():101-130. PubMed ID: 35101228
[TBL] [Abstract][Full Text] [Related]
29. Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens.
Walters DM; Stokes JB; Adair SJ; Stelow EB; Borgman CA; Lowrey BT; Xin W; Blais EM; Lee JK; Papin JA; Parsons JT; Bauer TW
PLoS One; 2013; 8(10):e77065. PubMed ID: 24204737
[TBL] [Abstract][Full Text] [Related]
30. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
Kutschat AP; Hamdan FH; Wang X; Wixom AQ; Najafova Z; Gibhardt CS; Kopp W; Gaedcke J; Ströbel P; Ellenrieder V; Bogeski I; Hessmann E; Johnsen SA
Cancer Res; 2021 Jun; 81(11):2943-2955. PubMed ID: 33436389
[TBL] [Abstract][Full Text] [Related]
31. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
32. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Miyabayashi K; Ijichi H; Mohri D; Tada M; Yamamoto K; Asaoka Y; Ikenoue T; Tateishi K; Nakai Y; Isayama H; Morishita Y; Omata M; Moses HL; Koike K
Cancer Res; 2013 Apr; 73(7):2221-34. PubMed ID: 23378339
[TBL] [Abstract][Full Text] [Related]
33. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
34. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Kang YW; Lee JE; Jung KH; Son MK; Shin SM; Kim SJ; Fang Z; Yan HH; Park JH; Han B; Cheon MJ; Woo MG; Lim JH; Kim YS; Hong SS
Cancer Lett; 2018 Dec; 438():174-186. PubMed ID: 30217561
[TBL] [Abstract][Full Text] [Related]
35. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC).
Er JL; Goh PN; Lee CY; Tan YJ; Hii LW; Mai CW; Chung FF; Leong CO
Apoptosis; 2018 Jun; 23(5-6):343-355. PubMed ID: 29740790
[TBL] [Abstract][Full Text] [Related]
36. AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia.
Norris AM; Gore A; Balboni A; Young A; Longnecker DS; Korc M
Oncogene; 2013 Aug; 32(33):3867-76. PubMed ID: 22945649
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
38. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract][Full Text] [Related]
39. SMAD4 Y353C promotes the progression of PDAC.
Wang Z; Li Y; Zhan S; Zhang L; Zhang S; Tang Q; Li M; Tan Z; Liu S; Xing X
BMC Cancer; 2019 Nov; 19(1):1037. PubMed ID: 31684910
[TBL] [Abstract][Full Text] [Related]
40. Par-4 mediated Smad4 induction in PDAC cells restores canonical TGF-β/ Smad4 axis driving the cells towards lethal EMT.
Mohd Faheem M; Rasool RU; Ahmad SM; Jamwal VL; Chakraborty S; Katoch A; Gandhi SG; Bhagat M; Goswami A
Eur J Cell Biol; 2020 May; 99(4):151076. PubMed ID: 32439219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
